Shares of Torrent Pharmaceuticals Limited closed today at Rs 1,835.80. The scrip witnessed an intra-day high of Rs 1,884.90 exhibiting an increase of 10 percent in comparison to the previous close levels of Rs 1,713.55. The intra-day high discussed above was marked as the company’s 52-week high figure. It has a market capitalization of Rs 62,131 crores.
Such a movement in the stock prices today is witnessed after the company, through a regulatory filing with the BSE, announced its Q4 as well as Annual results for FY2022-23. Details pertaining to the same are been discussed later on in the report.
Moreover, the company’s Board recommended a Final dividend of Rs 8 (160 percent of its Face Value of Rs 5) for the same financial year. Payment of the same is subject to shareholder approval.
Torrent Pharmaceuticals Limited is a drug-manufacturing company with its prime focus on the central nervous system, cardiovascular, and gastro-intestinal therapeutic areas. Geographically, the company’s business activities are been carried out across the Indian and International markets.
Comparing Q4FY21-22 v/s Q4FY22-23, the operating revenues of the company moved up from Rs 2,131 crores to Rs 2,491 crores. Moreover, the company’s net profits, during the same period, transitioned from losses of Rs 118 crores to profits of Rs 287 crores.
On a YoY basis, the above-mentioned metrics have been successful in showing improvements with the operating revenues increasing from Rs 8,508 crores during FY21-22 to Rs 9,620 crores in FY22-23 and the net profits, keeping the timeframe the same, moving from Rs 777 crores to Rs 1,245 crores indicating an increase of about 60 percent.
Having a say on the basic profit margins, the net profit margins of the company have increased from 9.13 percent during FY21-22 to 12.94 percent in FY22-23.
As per the latest shareholding data available for the quarter ending March 2023, Promoters of the company hold a 71.25 percent stake, and Foreign Institutional Investors hold a 12.04 percent stake in the company.
Written by Amit Madnani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
